For the quarter ending 2026-03-31, XLO had $12,808K increase in cash & cash equivalents over the period. -$22,899K in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -9,529 | 10,360 | -16,287 | -29,109 |
| Issuance costs allocated to common stock warrant liabilities | - | 0 | 0 | 2,284 |
| Depreciation and amortization | 344 | 323 | 340 | 878 |
| Stock-based compensation expense | 2,211 | 2,930 | 1,123 | 2,886 |
| Change in fair value of common stock warrant liabilities | -3,300 | -21,275 | 15,380 | 50 |
| Collaboration and license agreement receivable | -5,000 | -12,500 | 17,500 | - |
| Prepaid and other assets | 1,205 | -495 | 500 | -3,080 |
| Accounts payable | -1,680 | 428 | -1,798 | 1,522 |
| Accrued expenses and other liabilities | -1,536 | 928 | 3,312 | -5,219 |
| Deferred revenue | -12,648 | -8,687 | -1,565 | 38,129 |
| Net cash (used in) provided by operating activities | -22,343 | -1,998 | -17,495 | 14,501 |
| Purchases of property and equipment | 556 | 95 | 0 | 423 |
| Net cash used in investing activities | -556 | -95 | 0 | -423 |
| Proceeds from issuance of prefunded warrants and common stock warrants in connection with a follow-on offering, net of issuance costs | - | 47,033 | - | - |
| Proceeds from the issuance of common stock, prefunded warrants and liabilities to issue common stock in connection with the exercise of series b warrants, net of issuance costs | - | 35,828 | - | - |
| Proceeds from issuance of common stock in connection with sale of stock-Follow On Offering | - | - | -285 | 47,318 |
| Proceeds from issuance of common stock-Exercise Of Prefunded Warrants | - | 1 | - | - |
| Proceeds from issuance of common stock-Private Placement Abbvie Inc.Stock Purchase Agreement | - | 0 | 0 | 2,810 |
| Proceeds from issuance of prefunded warrants in connection with a follow-on offering, net of issuance costs | 37,256 | - | - | - |
| Proceeds from issuance of common stock | 0 | 0 | 0 | 2,017 |
| Proceeds from issuance of common stock under employee stock purchase plan | - | 36 | 0 | 40 |
| Proceeds from exercise of stock options | 1 | 1 | 0 | 9 |
| Payments of issuance costs included in accounts payable or accrued expenses at prior year end | 1,550 | - | - | - |
| Net cash provided by financing activities | 35,707 | 35,866 | -285 | 52,194 |
| Increase in cash, cash equivalents and restricted cash | 12,808 | 33,773 | -17,780 | 66,272 |
| Cash, cash equivalents and restricted cash, beginning of period | 139,338 | 105,565 | 57,073 | - |
| Cash, cash equivalents and restricted cash, end of period | 152,146 | 139,338 | 105,565 | - |
Xilio Therapeutics, Inc. (XLO)
Xilio Therapeutics, Inc. (XLO)